Bharat Immunologicals & Biologicals Corporation Ltd. significantly underperforms in comparison to its peers across all key financial metrics, indicating a strong need for improvement in growth, profitability, and financial stability. The analysis highlights Sun Pharmaceutical Industries Ltd. and Cipla Ltd. as strong performers, while Bharat Immunologicals stands out as financially weak and undervalued.

• • Bharat Immunologicals has a PE ratio of -5.62, indicating negative earnings and poor profitability.
• • Sun Pharmaceutical and Cipla are leaders in growth, profitability, and efficiency metrics.
• • Bharat Immunologicals has no revenue or earnings growth, resulting in a low valuation appeal.
• • The sector shows strong growth potential with several companies achieving double-digit revenue growth.